Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

This publication has 36 references indexed in Scilit:

• Epigenetic and genetic features of 24 colon cancer cell lines
  Oncogenesis, 2013
• Comprehensive molecular characterization of human colon and rectal cancer
  Nature, 2012
• Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
  Cancer Discovery, 2011
• A decade of exploring the cancer epigenome — biological and translational implications
  Nature Reviews Cancer, 2011
• Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis
  BMC Bioinformatics, 2010
• A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
  PLOS ONE, 2010
• Sensitive digital quantification of DNA methylation in clinical samples
  Nature Biotechnology, 2009
• Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
  Cancer Research, 2008
• SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response
  British Journal of Cancer, 2008
• Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy
  Clinical Cancer Research, 2007